

Thermax

20 June 2020

Reuters: THMX.BO; Bloomberg: TMX IN

COVID-19 to impact order inflow; Topline growth a challenge

Thermax posted 4QFY20 consolidated revenue of Rs13.2bn, down 36% YoY and 11%/17% below our/consensus estimates, as COVID-19 lockdown led to loss of sales worth Rs4bn-Rs5bn due to disruption in business activities of Thermax and its customers. Energy/Environment/Chemical segment sales declined 39%/26%/6% YoY to Rs10.5bn/Rs963mn, respectively. Gross margin rose to 49.1% in 4QFY20 vs. 39.5% YoY and 44.4% QoQ. EBITDA fell 63% YoY to Rs636mn, leading to EBITDA margin of 4.8%, down 340bps YoY, much below our/consensus estimate of 7.4%/6.8%. EBIT margin of Energy/Environment segments fell 490bps/340bps YoY to 3.1%/8.2%. EBIT margin of the Chemical segment was up 200bps YoY to 18.6%. PAT declined 69% YoY to Rs390mn, below our/consensus estimate of Rs994mn/Rs946mn due to lower sales. Consolidated order inflow in 4Q/FY20 fell 18%/2% YoY to Rs9.5bn/Rs54.9bn while order backlog was down 2% YoY to Rs52.4bn. Thermax expects order inflow to be lower in FY21E as large size orders from sectors such as steel, cement & fertilizers are likely to be deferred. It expects business normalcy to return by 3QFY21 and has embarked on a cost cutting drive to tide over a challenging year. We downgrade the stock to Accumulate (from Buy) with a revised target price of Rs785 (Rs900 earlier) based on 27x revised FY22E earnings, factoring in COVID-19 impact.

Order book position: Thermax posted consolidated order inflow of Rs9.5bn in 4QFY20, down 18% YoY. Past three years' average quarterly run-rate is Rs14.5bn. Domestic order inflow fell by 11% YoY to Rs5.9bn while international inflow declined 27% YoY to Rs3.6bn. Order inflow in FY20 fell 2% YoY to Rs54.9bn with Energy/Environment/Chemical segments mix at Rs32.8bn/Rs17.8bn/Rs4.4bn. Order book fell by 2% YoY to Rs52.4bn with Energy/Environment/Chemical mix of Rs35.6bn/Rs16bn/Rs800mn. The order book excludes slow moving orders worth Rs2bn. Domestic/International order book breakup is Rs37.9bn/Rs14.4bn. In the domestic market, Thermax won two large FGD orders worth Rs9bn followed by orders from food, food processing and oil & gas industries in FY20. The order inflow in FY21E is likely to be lower as large sized orders from sectors such as steel, cement and fertilizers are likely to get deferred. Thermax expects orders from sectors such as oil & gas (~Rs10bn), pharma, food, FMCG and dairy industries.

Key business updates: (1) Thermax' domestic factories have resumed operation with 25% to 50% capacity utilization, while its overseas plants in Denmark, Germany and Poland are running with 50% capacity. (2) Thermax' Dahej plant will likely see production loss of 30-45 days as it has been shut after a fire accident. (3) 84% of Thermax's customers are ready to go ahead with their project execution, 90% of the construction sites have resumed operations (with 50%-60% of labour force retained) and 56% of the vendors are not facing any labour/liquidity issues. (4) Working capital position improved to Rs1.3bn in FY20 vs. Rs2bn YoY. (5) Chemical segment is expected to report double digit growth in FY21E as it expects healthy orders from North America and Europe for specialty chemicals like resin. (5) Danstoker made a loss in FY20, but will break-even from 1QFY21 onwards due to cost cutting & change in management. Losses at Indonesia operations have reduced. (6) FGD orders from private sector are likely while NTPC's Lot 6 will be bid out in FY21E. (7) Thermax would incur additional cost of ~Rs250mn post COVID-19 towards safety practices, which it aims to offset by cost rationalisation in other areas. Thermax would bill the additional safety cost in new project bids. (8) Other expenses were higher due to Rs150mn warranty provision, Rs150mn forex loss (vs. Rs60mn gain YoY), write off of bad debts and higher freight outward charges.

Outlook: We expect Thermax to report 2% CAGR decline in revenue over FY20-FY22E due to COVID-19 impact and lower order book. While we expect PBT CAGR of 8%, the earnings CAGR would be higher at 24% due to favourable tax rate (at 25.17% in FY21E/FY22E versus 43% in FY20).

ACCUMULATE

Sector: Capital Goods

CMP: Rs748

Target Price: Rs785

Upside: 5%

Chirag Muchhala

Research Analyst chirag.muchhala@nirmalbang.com

+91-22-6273 8092

Rahulkumar Mishra

Research Associate rahulkumar.mishra@nirmalbang.com +91-22-6273 8028

| Key Data | |
|--------------------------|----------|
| Current Shares O/S (mn) | 119.2 |
| Mkt Cap (Rsbn/US\$bn) | 89.6/1.2 |
| 52 Wk H / L (Rs) | 1181/570 |
| Daily Vol. (3M NSE Avg.) | 172,586 |

Price Performance (%)

| | 1 M | 6 M | 1 Yr |
|-------------|------|--------|--------|
| Thermax | 5.8 | (28.1) | (28.7) |
| Nifty Index | 15.4 | (16.4) | (12.4) |

Source: Bloomberg

| Y/E March (Rsmn) | 4QFY19 | 3QFY20 | 4QFY20 | YoY (%) | QoQ (%) | FY19 | FY20 | YoY (%) |
|------------------------|--------|--------|--------|---------|---------|--------|--------|---------|
| Net revenues | 20,737 | 14,101 | 13,230 | (36.2) | (6.2) | 59,732 | 57,313 | (4.0) |
| Raw material costs | 12,553 | 7,847 | 6,733 | (46.4) | (14.2) | 33,367 | 30,857 | (7.5) |
| Staff costs | 2,051 | 1,999 | 1,972 | (3.8) | (1.4) | 7,675 | 7,990 | 4.1 |
| Other expenses | 4,425 | 3,123 | 3,889 | (12.1) | 24.5 | 14,116 | 14,404 | 2.0 |
| Total expenditure | 19,029 | 12,969 | 12,594 | (33.8) | (2.9) | 55,157 | 53,251 | (3.5) |
| EBITDA | 1,708 | 1,132 | 636 | (62.8) | (43.8) | 4,574 | 4,062 | (11.2) |
| EBITDA margin (%) | 8.2 | 8.0 | 4.8 | , , | , , | 7.7 | 7.1 | , , |
| Depreciation | 247 | 316 | 308 | 24.8 | (2.5) | 920 | 1,166 | 26.7 |
| Interest costs | 35 | 19 | 49 | 39.6 | 153.9 | 143 | 150 | 4.9 |
| Other income | 520 | 258 | 307 | (40.9) | 19.2 | 1,499 | 1,000 | (33.3) |
| Exceptional items | (20) | - | - | , , | | (895) | · - | . , |
| PBT | 1,925 | 1,054 | 586 | (69.6) | (44.4) | À,11Á | 3,745 | (9.0) |
| Tax | 653 | 205 | 196 | (70.0) | (4.4) | 849 | 1,621 | 90.8 |
| Profit from associates | (4) | - | - | , , | , | (11) | - | NA |
| PAT | 1,269 | 850 | 390 | (69.2) | (54.1) | 3,254 | 2,125 | (34.7) |
| PAT margin (%) | 6.1 | 6.0 | 3.0 | . , | . , | 5.4 | 3.7 | . , |
| EPS (Rs) | 11.3 | 7.5 | 3.5 | (69.2) | (54.1) | 28.9 | 18.9 | (34.7) |

Source: Company, Nirmal Bang Institutional Equities Research



Exhibit 1: Financial summary (consolidated)

| Y/E March (Rsmn) | FY18 | FY19 | FY20 | FY21E | FY22E |
|--------------------|--------|--------|--------|--------|--------|
| Net sales | 44,649 | 59,732 | 57,313 | 50,583 | 54,921 |
| EBITDA | 4,009 | 4,574 | 4,062 | 3,642 | 4,394 |
| Net profit | 2,321 | 3,254 | 2,125 | 2,628 | 3,274 |
| EPS (Rs) | 20.6 | 28.9 | 18.9 | 23.3 | 29.1 |
| EPS growth (%) | 4.1 | 40.2 | (34.7) | 23.7 | 24.6 |
| EBITDA margin (%) | 9.0 | 7.7 | 7.1 | 7.2 | 8.0 |
| P/E (x) | 36.3 | 25.9 | 39.6 | 32.1 | 25.7 |
| P/BV (x) | 3.1 | 2.8 | 2.8 | 2.6 | 2.4 |
| EV/EBITDA (x) | 20.8 | 18.1 | 20.1 | 22.7 | 18.4 |
| Dividend yield (%) | 0.8 | 0.9 | 0.9 | 0.9 | 1.2 |
| RoCE (%) | 11.4 | 11.9 | 8.9 | 7.2 | 8.8 |
| RoE (%) | 9.8 | 14.5 | 7.0 | 8.4 | 9.8 |

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 2: Consolidated segment-wise snapshot

| - | | = | | | | | |
|--------|--|--|--|--|---|--|---|
| 4QFY19 | 3QFY20 | 4QFY20 | YoY (%) | QoQ (%) | FY19 | FY20 | YoY (%) |
| | | | | | | | |
| 17,184 | 11,208 | 10,512 | (38.8) | (6.2) | 47,995 | 46,770 | (2.6) |
| 2,677 | 1,974 | 1,991 | (25.6) | 0.9 | 8,283 | 7,220 | (12.8) |
| 1,025 | 1,168 | 963 | (6.1) | (17.6) | 4,151 | 4,213 | 1.5 |
| | | | | | | | |
| 82.3 | 78.1 | 78.1 | - | - | 79.4 | 80.4 | - |
| 12.8 | 13.8 | 14.8 | - | - | 13.7 | 12.4 | - |
| 4.9 | 8.1 | 7.1 | - | - | 6.9 | 7.2 | - |
| | | | | | | | |
| 1,368 | 647 | 323 | (76.4) | (50.1) | 3,218 | 2,493 | (22.5) |
| 311 | 103 | 162 | (47.7) | 58.2 | 567 | 381 | (32.9) |
| 170 | 289 | 179 | 4.9 | (38.1) | 617 | 780 | 26.4 |
| | | | | | | | |
| 8.0 | 5.8 | 3.1 | - | - | 6.7 | 5.3 | - |
| 11.6 | 5.2 | 8.2 | - | - | 6.8 | 5.3 | - |
| 16.6 | 24.7 | 18.6 | - | - | 14.9 | 18.5 | - |
| | 17,184 2,677 1,025 82.3 12.8 4.9 1,368 311 170 | 17,184 11,208 2,677 1,974 1,025 1,168 82.3 78.1 12.8 13.8 4.9 8.1 1,368 647 311 103 170 289 8.0 5.8 11.6 5.2 | 17,184 11,208 10,512 2,677 1,974 1,991 1,025 1,168 963 82.3 78.1 78.1 12.8 13.8 14.8 4.9 8.1 7.1 1,368 647 323 311 103 162 170 289 179 8.0 5.8 3.1 11.6 5.2 8.2 | 17,184 11,208 10,512 (38.8) 2,677 1,974 1,991 (25.6) 1,025 1,168 963 (6.1) 82.3 78.1 78.1 - 12.8 13.8 14.8 - 4.9 8.1 7.1 - 1,368 647 323 (76.4) 311 103 162 (47.7) 170 289 179 4.9 8.0 5.8 3.1 - 11.6 5.2 8.2 - | 17,184 11,208 10,512 (38.8) (6.2) 2,677 1,974 1,991 (25.6) 0.9 1,025 1,168 963 (6.1) (17.6) 82.3 78.1 78.1 - - 12.8 13.8 14.8 - - 4.9 8.1 7.1 - - 1,368 647 323 (76.4) (50.1) 311 103 162 (47.7) 58.2 170 289 179 4.9 (38.1) 8.0 5.8 3.1 - - 11.6 5.2 8.2 - - | 17,184 11,208 10,512 (38.8) (6.2) 47,995 2,677 1,974 1,991 (25.6) 0.9 8,283 1,025 1,168 963 (6.1) (17.6) 4,151 82.3 78.1 78.1 - - 79.4 12.8 13.8 14.8 - - 13.7 4.9 8.1 7.1 - - 6.9 1,368 647 323 (76.4) (50.1) 3,218 311 103 162 (47.7) 58.2 567 170 289 179 4.9 (38.1) 617 8.0 5.8 3.1 - - 6.7 11.6 5.2 8.2 - - 6.8 | 17,184 11,208 10,512 (38.8) (6.2) 47,995 46,770 2,677 1,974 1,991 (25.6) 0.9 8,283 7,220 1,025 1,168 963 (6.1) (17.6) 4,151 4,213 82.3 78.1 78.1 - - 79.4 80.4 12.8 13.8 14.8 - - 13.7 12.4 4.9 8.1 7.1 - - 6.9 7.2 1,368 647 323 (76.4) (50.1) 3,218 2,493 311 103 162 (47.7) 58.2 567 381 170 289 179 4.9 (38.1) 617 780 8.0 5.8 3.1 - - 6.7 5.3 11.6 5.2 8.2 - - 6.8 5.3 |

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 3: Actual performance versus our estimate, Bloomberg consensus (consolidated)

| 4QFY20 (Rsmn) | Actual | Our estimate | Deviation (%) | Bloomberg consensus | Deviation (%) |
|---------------|--------|--------------|---------------|---------------------|---------------|
| Revenues | 13,230 | 14,937 | (11.4) | 15,935 | (17.0) |
| EBITDA | 636 | 1,109 | (42.7) | 1,087 | (41.5) |
| PAT | 390 | 994 | (60.7) | 946 | (58.7) |

Source: Company, Bloomberg, Nirmal Bang Institutional Equities Research


Exhibit 4: Change in our estimates

| (Rsmn) | Old | Old | | | Deviatio | n (%) |
|-----------|--------|--------|--------|--------|----------|--------|
| Y/E March | FY21E | FY22E | FY21E | FY22E | FY21E | FY22E |
| Revenues | 63,346 | 71,091 | 50,583 | 54,921 | (20.1) | (22.7) |
| EBITDA | 4,878 | 5,972 | 3,642 | 4,394 | (25.3) | (26.4) |
| PAT | 3,593 | 4,413 | 2,628 | 3,274 | (26.9) | (25.8) |

Source: Company, Nirmal Bang Institutional Equities Research


2 Thermax

Exhibit 5: Consolidated order backlog trend




Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 6: Consolidated order inflow trend



Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 7: P/E charts



Source: BSE, Nirmal Bang Institutional Equities Research



Financial statements (consolidated)

Exhibit 8: Income statement

| Y/E March (Rsmn) | FY18 | FY19 | FY20 | FY21E | FY22E |
|------------------------------|--------|--------|--------|--------|--------|
| Net sales | 44,649 | 59,732 | 57,313 | 50,583 | 54,921 |
| % growth | (0.4) | 33.8 | (4.0) | (11.7) | 8.6 |
| Raw material costs | 23,493 | 33,367 | 30,857 | 26,961 | 29,108 |
| Staff costs | 6,805 | 7,675 | 7,990 | 7,588 | 8,238 |
| Other overheads | 10,341 | 14,116 | 14,404 | 12,393 | 13,181 |
| Total expenditure | 40,639 | 55,157 | 53,251 | 46,941 | 50,528 |
| EBITDA | 4,009 | 4,574 | 4,062 | 3,642 | 4,394 |
| % growth | (7.4) | 14.1 | (11.2) | (10.3) | 20.6 |
| EBITDA margin (%) | 9.0 | 7.7 | 7.1 | 7.2 | 8.0 |
| Other income | 1,164 | 1,499 | 1,000 | 1,250 | 1,405 |
| Interest costs | 129 | 143 | 150 | 148 | 141 |
| Depreciation | 824 | 920 | 1,166 | 1,232 | 1,283 |
| Profit before tax | 4,220 | 5,010 | 3,745 | 3,512 | 4,375 |
| Tax | 1,658 | 849 | 1,621 | 884 | 1,101 |
| Net profit | 2,563 | 4,160 | 2,125 | 2,628 | 3,274 |
| Profit from associates & JVs | (242) | (11) | - | - | - |
| Extra-ordinary items | - | (895) | - | - | - |
| Reported PAT | 2,321 | 3,254 | 2,125 | 2,628 | 3,274 |
| % growth | 4.1 | 40.2 | (34.7) | 23.7 | 24.6 |
| PAT margin (%) | 5.2 | 6.9 | 3.7 | 5.2 | 6.0 |
| EPS (Rs) | 20.6 | 28.9 | 18.9 | 23.3 | 29.1 |
| % growth | 4.1 | 40.2 | (34.7) | 23.7 | 24.6 |

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 10: Balance sheet

| Y/E March (Rsmn) | FY18 | FY19 | FY20 | FY21E | FY22E |
|--|--------|---------|---------|---------|---------|
| Share capital | 225 | 225 | 225 | 225 | 225 |
| Reserves | 26,922 | 29,918 | 30,054 | 31,894 | 34,154 |
| Net worth | 27,147 | 30,143 | 30,279 | 32,119 | 34,379 |
| Short-term loans | 1,642 | 1,850 | 1,782 | 1,782 | 1,582 |
| Long-term loans | 530 | 351 | 334 | 334 | 334 |
| Total loans | 2,173 | 2,201 | 2,115 | 2,115 | 1,915 |
| Deferred tax liability (net) | (917) | (2,120) | (1,510) | (1,510) | (1,510) |
| Total liabilities | 28,403 | 30,223 | 30,885 | 32,725 | 34,785 |
| Net block | 8,207 | 12,550 | 12,248 | 12,516 | 12,733 |
| Capital work-in-progress | 1,034 | 401 | 553 | 200 | 200 |
| Goodwill | 1,520 | 569 | 590 | 590 | 590 |
| Investments | 14,717 | 8,293 | 8,752 | 8,752 | 8,752 |
| Inventories | 3,666 | 5,086 | 4,546 | 4,435 | 4,665 |
| Debtors | 12,992 | 14,385 | 14,785 | 13,858 | 14,596 |
| Cash | 2,940 | 3,691 | 4,761 | 3,820 | 5,462 |
| Other current assets | 13,292 | 20,805 | 11,772 | 12,726 | 15,322 |
| Total current assets | 32,891 | 43,967 | 35,864 | 34,838 | 40,044 |
| Creditors | 10,605 | 13,994 | 10,000 | 8,495 | 9,969 |
| Other current liabilities & provisions | 19,361 | 21,563 | 17,121 | 15,676 | 17,565 |
| Total current liabilities | 29,966 | 35,557 | 27,120 | 24,171 | 27,533 |
| Net current assets | 2,925 | 8,410 | 8,743 | 10,667 | 12,511 |
| Total assets | 28,403 | 30,223 | 30,885 | 32,725 | 34,785 |

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 9: Cash flow

| Y/E March (Rsmn) | FY18 | FY19 | FY20 | FY21E | FY22E |
|-------------------------------------|---------|---------|---------|---------|---------|
| EBIT | 3,185 | 3,654 | 2,896 | 2,410 | 3,111 |
| (Inc.)/dec. in working capital | 3,164 | (4,735) | 737 | (2,866) | (200) |
| Cash flow from operations | 6,349 | (1,080) | 3,633 | (456) | 2,910 |
| Other income | 1,164 | 1,499 | 1,000 | 1,250 | 1,405 |
| Depreciation | 824 | 920 | 1,166 | 1,232 | 1,283 |
| Tax paid (-) | (1,581) | (2,053) | (1,010) | (884) | (1,101) |
| Minority interest / profit from JVs | (242) | (11) | - | - | - |
| Net cash from operations | 6,514 | (725) | 4,789 | 1,142 | 4,497 |
| Capital expenditure (-) | (1,999) | (4,630) | (1,016) | (1,147) | (1,500) |
| Net cash after capex | 4,515 | (5,355) | 3,774 | (5) | 2,997 |
| Interest paid (-) | (129) | (143) | (150) | (148) | (141) |
| Dividends paid (-) | (811) | (946) | (946) | (788) | (1,013) |
| Inc./(dec.) in short-term borrowing | 790 | 208 | (69) | - | (200) |
| Inc./(dec.) in long-term borrowing | 70 | (179) | (17) | - | - |
| Inc./(dec.) in total borrowings | 860 | 28 | (85) | - | (200) |
| (Inc.)/dec. in investments | (3,887) | 6,424 | (459) | - | - |
| Minority interest | (14) | - | - | - | - |
| Cash from financial activities | (3,980) | 5,363 | (1,640) | (936) | (1,354) |
| Others | 195 | 742 | (1,063) | - | - |
| Opening cash balance | 2,210 | 2,940 | 3,691 | 4,761 | 3,820 |
| Closing cash balance | 2,940 | 3,691 | 4,761 | 3,820 | 5,462 |
| Change in cash balance | 730 | 751 | 1,070 | (941) | 1,643 |

Source: Company, Nirmal Bang Institutional Equities Research

Exhibit 11: Key ratios

| FY18 | FY19 | FY20 | FY21E | FY22E |
|-------|---|---|---|--|
| | | | | |
| 20.6 | 28.9 | 18.9 | 23.3 | 29.1 |
| 241.1 | 267.7 | 268.9 | 285.2 | 305.3 |
| | | | | |
| 36.3 | 25.9 | 39.6 | 32.1 | 25.7 |
| 3.1 | 2.8 | 2.8 | 2.6 | 2.4 |
| 20.8 | 18.1 | 20.1 | 22.7 | 18.4 |
| 1.9 | 1.4 | 1.4 | 1.6 | 1.5 |
| | | | | |
| 11.4 | 11.9 | 8.9 | 7.2 | 8.8 |
| 9.8 | 14.5 | 7.0 | 8.4 | 9.8 |
| 25.2 | 22.8 | 14.8 | 11.9 | 14.2 |
| | | | | |
| 9.0 | 7.7 | 7.1 | 7.2 | 8.0 |
| 7.1 | 6.1 | 5.1 | 4.8 | 5.7 |
| 5.2 | 6.9 | 3.7 | 5.2 | 6.0 |
| | | | | |
| 1.7 | 2.0 | 1.9 | 1.6 | 1.6 |
| 106 | 88 | 94 | 100 | 97 |
| 30 | 31 | 29 | 32 | 31 |
| 165 | 153 | 118 | 115 | 125 |
| | 20.6 241.1 36.3 3.1 20.8 1.9 11.4 9.8 25.2 9.0 7.1 5.2 | 20.6 28.9 241.1 267.7 36.3 25.9 3.1 2.8 20.8 18.1 1.9 1.4 11.4 11.9 9.8 14.5 25.2 22.8 9.0 7.7 7.1 6.1 5.2 6.9 1.7 2.0 106 88 30 31 | 20.6 28.9 18.9 241.1 267.7 268.9 36.3 25.9 39.6 3.1 2.8 2.8 20.8 18.1 20.1 1.9 1.4 1.4 11.4 11.9 8.9 9.8 14.5 7.0 25.2 22.8 14.8 9.0 7.7 7.1 7.1 6.1 5.1 5.2 6.9 3.7 1.7 2.0 1.9 106 88 94 30 31 29 | 20.6 28.9 18.9 23.3 241.1 267.7 268.9 285.2 36.3 25.9 39.6 32.1 3.1 2.8 2.8 2.6 20.8 18.1 20.1 22.7 1.9 1.4 1.4 1.6 11.4 11.9 8.9 7.2 9.8 14.5 7.0 8.4 25.2 22.8 14.8 11.9 9.0 7.7 7.1 7.2 7.1 6.1 5.1 4.8 5.2 6.9 3.7 5.2 1.7 2.0 1.9 1.6 106 88 94 100 30 31 29 32 |

Source: Company, Nirmal Bang Institutional Equities Research



Rating track


| Date | Rating | Market price (Rs) | Target price (Rs) |
|------------------|------------|-------------------|-------------------|
| 27January 2012 | Sell | 495 | 383 |
| 3 February 2012 | Sell | 522 | 375 |
| 13 April 2012 | Sell | 445 | 375 |
| 14 May 2012 | Sell | 421 | 378 |
| 27 July 2012 | Sell | 480 | 378 |
| 4 October 2012 | Sell | 561 | 378 |
| 31 October 2012 | Sell | 585 | 421 |
| 3 December 2012 | Sell | 590 | 467 |
| 7 January 2013 | Sell | 617 | 467 |
| 4 February 2013 | Sell | 582 | 467 |
| 9 April 2013 | Sell | 573 | 467 |
| 23 May 2013 | Sell | 589 | 486 |
| 8 July 2013 | Sell | 617 | 541 |
| 9 July 2013 | Sell | 621 | 541 |
| 26 July 2013 | Sell | 592 | 541 |
| 7 October 2013 | Sell | 592 | 541 |
| 8 November 2013 | Sell | 620 | 530 |
| 10 December 2013 | Sell | 669 | 530 |
| 7 January 2014 | Sell | 695 | 530 |
| 22 January 2014 | Sell | 650 | 583 |
| 11 April 2014 | Sell | 759 | 583 |
| 29 May 2014 | Sell | 898 | 787 |
| 10 July 2014 | Sell | 924 | 787 |
| 24 July 2014 | Sell | 909 | 712 |
| 9 October 2014 | Sell | 862 | 712 |
| 5 November 2014 | Sell | 944 | 775 |
| 9 January 2015 | Sell | 1,042 | 775 |
| 3 February 2015 | Sell | 1,141 | 878 |
| 15 April 2015 | Sell | 1,077 | 878 |
| 28 May 2015 | Sell | 987 | 840 |
| 8 July 2015 | Sell | 1,042 | 840 |
| 30 July 2015 | Sell | 1,042 | 840 |
| 12 October 2015 | Sell | 857 | 840 |
| 29 October 2015 | Sell | 847 | 790 |
| 8 January 2016 | Sell | 881 | 790 |
| 2 February 2016 | Sell | 813 | 725 |
| 12 April 2016 | Sell | 747 | 725 |
| 27 May 2016 | Sell | 743 | 690 |
| 12 July 2016 | Sell | 891 | 690 |
| 12 August 2016 | Sell | 904 | 690 |
| 13 October 2016 | Sell | 893 | 690 |
| 15 November 2016 | Sell | 889 | 720 |
| 10 January 2017 | Sell | 798 | 720 |
| 10 February 2017 | Sell | 860 | 710 |
| 14 February 2017 | Sell | 866 | 780 |
| 7 April 2017 | Sell | 974 | 780 |
| 1 June 2017 | Sell | 1,010 | 840 |
| 6 July 2017 | Sell | 925 | 840 |
| 10 August 2017 | Sell | 874 | 815 |
| 9 October 2017 | Sell | 922 | 815 |
| 9 November 2017 | Sell | 1,000 | 870 |
| 9 January 2018 | Sell | 1,321 | 870 |
| 8 February 2018 | Sell | 1,167 | 985 |
| 6 April 2018 | Sell | 1,096 | 985 |
| 22 May 2018 | Sell | 1,147 | 965 |
| 10 July 2018 | Sell | 1,018 | 965 |
| 9 August 2018 | Sell | 1,108 | 965 |
| 9 October 2018 | Sell | 896 | 965 |
| 15 November 2018 | Sell | 1,018 | 960 |
| 9 January 2019 | Sell | 1,139 | 960 |
| 11 February 2019 | Sell | 1,065 | 965 |
| 9 April 2019 | Accumulate | 974 | 1,070 |
| 23 May 2019 | Accumulate | 981 | 1,040 |
| 9 July 2019 | Accumulate | 1,046 | 1,040 |
| 9 August 2019 | Accumulate | 1,090 | 1,040 |

Thermax



| 23 September 2019 | Accumulate | 1,110 | 1,160 |
|-------------------|------------|-------|-------|
| 7 October 2019 | Accumulate | 1,111 | 1,160 |
| 14 November 2019 | Accumulate | 1,070 | 1,170 |
| 9 January 2020 | Accumulate | 1,072 | 1,170 |
| 5 February 2020 | Accumulate | 1,070 | 1,160 |
| 26 March 2020 | Buy | 724 | 900 |
| 9 April 2020 | Buy | 712 | 900 |
| 20 June 2020 | Accumulate | 748 | 785 |

Rating track graph





DISCLOSURES

Research Reports that are published by Nirmal Bang Securities Private Limited (hereinafter referred to as "NBSPL") are for private circulation only. NBSPL is a registered Research Analyst under SEBI (Research Analyst) Regulations, 2014 having Registration no. INH000001766. NBSPL is also a registered Stock Broker with National Stock Exchange of India Limited, BSE Limited, Metropolitan Stock Exchange of India Limited, Multi Commodity Exchange of India Limited, National Commodity and Derivative Exchange Limited and Indian Commodity Exchange Limited in cash and Equity and Commodities derivatives segments.

NBSPL has other business divisions with independent research teams separated by Chinese walls, and therefore may, at times, have different or contrary views on stocks and markets.

NBSPL or its associates have not been debarred / suspended by SEBI or any other regulatory authority for accessing / dealing in securities Market. NBSPL, its associates or analyst or his relatives do not hold any financial interest (Except Investment) in the subject company. NBSPL or its associates or Analyst do not have any conflict or material conflict of interest at the time of publication of the research report with the subject company. NBSPL or its associates or Analyst or his relatives may or may not hold beneficial ownership of 1% or more in the subject company at the end of the month immediately preceding the date of publication of this research report.

NBSPL or its associates / analyst has not received any compensation / managed or co-managed public offering of securities of the company covered by Analyst during the past twelve months. NBSPL or its associates have not received any compensation or other benefits from the company covered by Analyst or third party in connection with the research report. Analyst has not served as an officer, director or employee of Subject Company. NBSPL / analyst has not been engaged in market making activity of the subject company.

Analyst Certification: I, Chirag Muchhala, the research analyst and Rahulkumar Mishra, Research Associate the authors of these reports, hereby certify that the views expressed in this research report accurately reflects my/our personal views about the subject securities, issuers, products, sectors or industries. It is also certified that no part of the compensation of the analyst(s) was, is, or will be directly or indirectly related to the inclusion of specific recommendations or views in this research. The analyst(s) principally responsible for the preparation of this research report and has taken reasonable care to achieve and maintain independence and objectivity in making any recommendations.

7



Disclaimer

Stock Ratings Absolute Returns

BUY > 15%

ACCUMULATE -5% to 15%

SELL < -5%

DISCLAIMER

This report is for the personal information of the authorized recipient and does not construe to be any investment, legal or taxation advice to you. NBSPL is not soliciting any action based upon it. Nothing in this research shall be construed as a solicitation to buy or sell any security or product, or to engage in or refrain from engaging in any such transaction. In preparing this research, we did not take into account the investment objectives, financial situation and particular needs of the reader.

This research has been prepared for the general use of the clients of NBSPL and must not be copied, either in whole or in part, or distributed or redistributed to any other person in any form. If you are not the intended recipient you must not use or disclose the information in this research in any way. Though disseminated to all the customers simultaneously, not all customers may receive this report at the same time. NBSPL will not treat recipients as customers by virtue of their receiving this report. This report is not directed or intended for distribution to or use by any person or entity resident in a state, country or any jurisdiction, where such distribution, publication, availability or use would be contrary to law, regulation or which would subject NBSPL & its group companies to registration or licensing requirements within such jurisdictions.

The report is based on the information obtained from sources believed to be reliable, but we do not make any representation or warranty that it is accurate, complete or up-to-date and it should not be relied upon as such. We accept no obligation to correct or update the information or opinions in it. NBSPL or any of its affiliates or employees shall not be in any way responsible for any loss or damage that may arise to any person from any inadvertent error in the information contained in this report. NBSPL or any of its affiliates or employees do not provide, at any time, any express or implied warranty of any kind, regarding any matter pertaining to this report, including without limitation the implied warranties of merchantability, fitness for a particular purpose, and non-infringement. The recipients of this report should rely on their own investigations.

This information is subject to change without any prior notice. NBSPL reserves its absolute discretion and right to make or refrain from making modifications and alterations to this statement from time to time. Nevertheless, NBSPL is committed to providing independent and transparent recommendations to its clients, and would be happy to provide information in response to specific client queries.

Before making an investment decision on the basis of this research, the reader needs to consider, with or without the assistance of an adviser, whether the advice is appropriate in light of their particular investment needs, objectives and financial circumstances. There are risks involved in securities trading. The price of securities can and does fluctuate, and an individual security may even become valueless. International investors are reminded of the additional risks inherent in international investments, such as currency fluctuations and international stock market or economic conditions, which may adversely affect the value of the investment. Opinions expressed are subject to change without any notice. Neither the company nor the director or the employees of NBSPL accept any liability whatsoever for any direct, indirect, consequential or other loss arising from any use of this research and/or further communication in relation to this research. Here it may be noted that neither NBSPL, nor its directors, employees, agents or representatives shall be liable for any damages whether direct or indirect, incidental, special or consequential including lost revenue or lost profit that may arise from or in connection with the use of the information contained in this report.

Copyright of this document vests exclusively with NBEPL.

Our reports are also available on our website www.nirmalbang.com

Access all our reports on Bloomberg, Thomson Reuters and Factset.

| Team Details: | | | | |
|----------------|------------------|-------------------------------|---|--|
| Name | | Email Id | Direct Line | |
| Rahul Arora | CEO | rahul.arora@nirmalbang.com | - | |
| Girish Pai | Head of Research | girish.pai@nirmalbang.com | +91 22 6273 8017 / 18 | |
| Dealing | | | | |
| Ravi Jagtiani | Dealing Desk | ravi.jagtiani@nirmalbang.com | +91 22 6273 8230, +91 22 6636 8833 | |
| Michael Pillai | Dealing Desk | michael.pillai@nirmalbang.com | +91 22 6273 8102/8103, +91 22 6636 8830 | |

Nirmal Bang Equities Pvt. Ltd.

Correspondence Address

B-2, 301/302, Marathon Innova,

Nr. Peninsula Corporate Park, Lower Parel (W), Mumbai-400013.

Board No.: 91 22 6273 8000/1; Fax.: 022 6273 8010

8 Thermax